Clinical trials
Completed Prostatic Hyperplasia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
97 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 4 |
| 2004 | 1 |
| 2005 | 6 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 10 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 97 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 8 |
| GlaxoSmithKline | 8 |
| Nymox Corporation | 5 |
| Northwestern University | 4 |
| University of California, San Francisco | 4 |
| Watson Pharmaceuticals | 4 |
| Boston Scientific Corporation | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3 |
| NeoTract, Inc. | 3 |
| Allergan | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Hyperplasia | 97 |
| Lower Urinary Tract Symptoms | 22 |
| Prostatic Neoplasms | 8 |
| Erectile Dysfunction | 3 |
| Hyperplasia | 3 |
| Nocturia | 3 |
| Urinary Bladder, Overactive | 3 |
| Anxiety Disorders | 2 |
| Diabetes Mellitus | 2 |
| Neoplasms | 2 |
Trials
Showing 1 to 25 of 97. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.